Story perspectives

Targeting NSD2 Reverses Drug Resistance in Prostate Cancer

11/28/2025

49 11

Summary

Story summary

A Nature study shows that targeting the epigenetic regulator NSD2 reverses drug resistance in neuroendocrine prostate cancer (CRPC-NE).
Using CRISPR-Cas9 on patient-derived organoids, researchers knocked out NSD2 and restored sensitivity to enzalutamide.
NSD2 knockout reinstated androgen receptor expression and reduced tumor growth in the organoids.
The findings position NSD2 as a promising target for clinical interventions and suggest combining NSD2 inhibitors with existing therapies to improve outcomes.

1 of 1

Story summary

A Nature study shows that targeting the epigenetic regulator NSD2 reverses drug resistance in neuroendocrine prostate cancer (CRPC-NE).
Using CRISPR-Cas9 on patient-derived organoids, researchers knocked out NSD2 and restored sensitivity to enzalutamide.
NSD2 knockout reinstated androgen receptor expression and reduced tumor growth in the organoids.
The findings position NSD2 as a promising target for clinical interventions and suggest combining NSD2 inhibitors with existing therapies to improve outcomes.